Takeda receives pricing approval of Nesina in Japan, triggering milestone for Furiex Pharma

14 June 2010

Japan's largest drugmaker Takeda Pharmaceutical received pricing approval for its type 2 diabetes drug Nesina (alogliptin), a highly selective DPP-4, from the Japanese Ministry of Health, Labor and Welfare on April 16, 2010.

North Carolina, USA-based Furiex Pharmaceuticals collaborated with Takeda to develop this product and, under the terms of their agreement, the US firm says it is now entitled to a $7.5 million milestone for the Japanese company.

'Receiving pricing approval for Nesina in Japan represents another important milestone for both Nesina and Furiex,' commented June Almenoff, president and chief medical officer of Furiex, announcing the latest development. "This approval confirms our strategy of developing innovative clinical development partnerships to bring new medicines to market,' she added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK